PMA device
Evolut PRO+ System, Evolut FX System, Evolut FX+ System
Medtronic, Inc. · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Aug 27, 2025, newest Aug 27, 2025Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
19
Naming "Evolut PRO+"
MAUDE reports
10,801
Brand "Evolut PRO+", since 2015
PubMed studies
217
Mentioning "Evolut PRO+"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Evolut PRO+ System, Evolut FX System, Evolut FX+ System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Evolut PRO+ System, Evolut FX System, Evolut FX+ SystemPMA supplement
P130021-S174 · Decided Aug 27, 2025 · 180 days after receipt · Panel Track
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Evolut PRO+", any status and sponsor, newest update first.
- Evolut PRO China Clinical StudyActive, not recruiting
Medtronic CardiovascularPublic (MDT)
NCT04982588 · 52 participants · Start Jul 17, 2021 · Primary completion Mar 17, 2023
Device: Medtronic CoreValve™ Evolut™ PRO System · For: Severe, Symptomatic Aortic Stenosis
Sites: Beijing, China; Chengdu, China; Hangzhou, China · 4 sites in all
- Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid StudyActive, not recruiting
Medtronic CardiovascularPublic (MDT)
NCT03635424 · 150 participants · Start Oct 30, 2018 · Primary completion Nov 13, 2019
Device: Medtronic TAVR Systems · For: Bicuspid Aortic Valve
Sites: Phoenix, Arizona; La Jolla, California; Thousand Oaks, California · 25 sites in all
- Balloon vs. Self Expanding Transcatheter Valve for Degenerated BioprosthesisPivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028
Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease
Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Evolut PRO+", and for the whole product code for context.
This brand
10,801 reports: 1,719 malfunction, 7,760 injury, 1,322 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
Medtronic Mexico S. De R.L. De CV
9617601-2026-06565 · Received Oct 30, 2026 · Event dated Sep 8, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- EVOLUT PRO PLUS VALVEInjury
Medtronic Mexico S. De R.L. De CV
9617601-2026-06585 · Received Oct 30, 2026 · Event dated Oct 5, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Cardiogenic Shock
- EVOLUT PRO PLUS VALVEMalfunction
Medtronic Mexico S. De R.L. De CV
9617601-2026-06586 · Received Oct 30, 2026 · Event dated Oct 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Particulates; Contamination /Decontamination Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Medtronic Heart Valves Division
Z-0559-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0560-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Medtronic Heart Valves Division
Z-0561-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Evolut PRO+"[tiab]. The summary above synthesizes these.
- Editorial: Going from Evolut PRO+ to Evolut FX: A step in the right direction.
Goel SS, Aoun J, Reardon MJ · Cardiovasc Revasc Med · 2024Editorial
- Coronary Access After TAVR.
Ochiai T, Chakravarty T, Yoon SH, et al. · JACC Cardiovasc Interv · 2020Observational Study, Research Support, Non-U.S. Gov't
- The Evolut R and Evolut PRO transcatheter aortic valve systems.
Choudhury T, Solomonica A, Bagur R · Expert Rev Med Devices · 2019Review
- Evolut PRO/PRO+ versus Evolut R system for transcatheter aortic valve replacement.
Bhogal S, Rogers T, Merdler I, et al. · Int J Cardiol · 2023Observational Study
- Short-Term Outcomes of ACURATE neo2.
Tobe A, Garg S, Möllmann H, et al. · Struct Heart · 2024Review
- From the Evolut Pro to the Evolut FX self-expanding transcatheter aortic valve replacement systems: current status and future perspectives.
Panagides V, Mesnier J, Nuche J, et al. · Expert Rev Med Devices · 2022Review
- PERCUTANEOUS TRANSAXILLARY TRANSCATHETER AORTIC VALVE IMPLANTATION.
Calheiros J, Boa A, Braga P, et al. · Port J Card Thorac Vasc Surg · 2021Case Reports
- First Report of Evolut Pro+ Transcatheter Aortic Valve-in-Valve in a Degenerated Lotus Valve.
Stolte T, Winkel D, Haaf P, et al. · Struct Heart · 2024
- Evolut PRO and SAPIEN ULTRA Performance in Small Aortic Annuli: The OPERA-TAVI Registry.
Scotti A, Sturla M, Costa G, et al. · JACC Cardiovasc Interv · 2024
- Evolut R and Evolut PRO vs. Sapien 3 for transcatheter aortic valve implantation - The 'generation gap' and beyond.
Gozdek M, Kowalewski M · Int J Cardiol · 2024Letter
- 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study.
Zahr F, Ramlawi B, Reardon MJ, et al. · JACC Cardiovasc Interv · 2024Multicenter Study, Research Support, Non-U.S. Gov't
- Risk of Coronary Obstruction Due to Sinus Sequestration in Redo Transcatheter Aortic Valve Replacement.
Ochiai T, Oakley L, Sekhon N, et al. · JACC Cardiovasc Interv · 2020Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.